The effect of anti-VEGF and various concentrations of N-methyllevamisole (7a) and suramin (5) recorded in the in vitro angiogenesis assay performed with HUVECs growing on a fibroblast monolayer.

<p>The images show HUVECs visualized by immunostaining for CD31 after treatment with: <i>A)</i> 1 mM <i>N</i>-methyllevamisole triflate (7a); <i>B)</i> 0.5 mM <i>N</i>-methyllevamisole triflate (<b>7a</b>); <i>C)</i> 0.25 mM <i>N</i>-methyllevamisole triflate (<b>7a</b>); <i>D)</i> 0.13 mM <i>N</i>-methyllevamisole triflate (<b>7a</b>); <i>E)</i> 0.06 mM <i>N</i>-methyllevamisole triflate (<b>7a</b>); <i>F)</i> 0.03 mM <i>N</i>-methyllevamisole triflate (<b>7a</b>); <i>G)</i> 0.02 mM <i>N</i>-methyllevamisole triflate (<b>7a</b>); <i>H)</i> 0.1 % DMSO (the control was diluted 1∶1000 corresponding the concentration of DMSO present in A); <i>I)</i> 5 μg/mL goat anti-recombinant human VEGF; <i>J)</i> 12 μM suramin (<b>5</b>); <i>K)</i> 1.5 μM suramin (<b>5</b>); <i>L)</i> medium (control); <i>M)</i> 10 mM BIS-TRIS; <i>N)</i> 10 mM BICINE; <i>O)</i> 10 mM <i>N</i>-methylimidazole; <i>P)</i> 1 mM <i>N</i>-methylimidazole.